<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25590926</article-id><article-id pub-id-type="pmc">4290737</article-id><article-id pub-id-type="doi">10.5935/abc.20140171</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Late Outcome of a Randomized Study on Oral Magnesium for Premature
Complexes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Falco</surname><given-names>Cristina N&#x000e1;dja M. Lima De</given-names></name><xref ref-type="aff" rid="aff01">1</xref><xref ref-type="aff" rid="aff02">2</xref><xref ref-type="corresp" rid="c01"/></contrib><contrib contrib-type="author"><name><surname>Darrieux</surname><given-names>Francisco Carlos da Costa</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Grupi</surname><given-names>Cesar</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Sacilotto</surname><given-names>Luciana</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Pisani</surname><given-names>Cristiano F.</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Lara</surname><given-names>Sissy</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Ramires</surname><given-names>Jos&#x000e9; A. F.</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Sosa</surname><given-names>Eduardo</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Tan Chen</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Hachul</surname><given-names>Denise</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Scanavacca</surname><given-names>Mauricio</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib></contrib-group><aff id="aff01"><label>1</label>Instituto do Cora&#x000e7;&#x000e3;o (INCOR/SP); S&#x000e3;o Paulo, SP -
Brazil</aff><aff id="aff02"><label>2</label>Cl&#x000ed;nica M&#x000e9;dica Core Vita, S&#x000e3;o Paulo, SP - Brazil</aff><author-notes><corresp id="c01"><bold>Mailing Address: Cristina N&#x000e1;dja Muniz Lima De Falco,</bold> Rua Cesar Henrique
Costa, 76, Santa Cruz. Postal Code 13.806-401, Mogi-Mirim, SP - Brazil. E-mail:
<email>cnmfalco@cardiol.br</email>; <email>cristinanadjadefalco@usp.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>12</month><year>2014</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>12</month><year>2014</year></pub-date><volume>103</volume><issue>6</issue><fpage>468</fpage><lpage>475</lpage><history><date date-type="received"><day>20</day><month>7</month><year>2014</year></date><date date-type="rev-recd"><day>17</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2014</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Ventricular and supraventricular premature complexes (PC) are frequent and usually
symptomatic. According to a previous study, magnesium pidolate (MgP)
administration to symptomatic patients can improve the PC density and
symptoms.</p></sec><sec><title>Objective</title><p>To assess the late follow-up of that clinical intervention in patients treated
with MgP or placebo.</p></sec><sec><title>Methods</title><p>In the first phase of the study, 90 symptomatic and consecutive patients with PC
were randomized (double-blind) to receive either MgP or placebo for 30 days.
Monthly follow-up visits were conducted for 15 months to assess symptoms and
control electrolytes. 24-hour Holter was performed twice, regardless of symptoms,
or whenever symptoms were present. In the second phase of the study, relapsing
patients, who had received MgP or placebo (crossing-over) in the first phase, were
treated with MgP according to the same protocol.</p></sec><sec><title>Results</title><p>Of the 45 patients initially treated with MgP, 17 (37.8%) relapsed during the
15-month follow-up, and the relapse time varied. Relapsing patients treated again
had a statistically significant reduction in the PC density of 138.25/hour (p &#x0003c;
0.001). The crossing-over patients reduced it by 247/hour (p &#x0003c; 0.001). Patients
who did not relapse, had a low PC frequency (3 PC/hour). Retreated patients had a
76.5% improvement in symptom, and crossing-over patients, 71.4%.</p></sec><sec><title>Conclusion</title><p>Some patients on MgP had relapse of symptoms and PC, indicating that MgP is
neither a definitive nor a curative treatment for late follow-up. However,
improvement in the PC frequency and symptoms was observed in the second phase of
treatment, similar to the response in the first phase of treatment.</p></sec></abstract><kwd-group><kwd>Ventricular Premature Complexes</kwd><kwd>Arrhythmias, Cardiac</kwd><kwd>Magnesium</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The incidence of premature ventricular complexe (PVC) and premature supraventricular
complexe (PsVC) increases with age, their prevalence being estimated at as much as 50%
of the general population<sup><xref rid="B01" ref-type="bibr">1</xref>-<xref rid="B05" ref-type="bibr">5</xref></sup>. The long-term prognosis is benign, but,
when symptomatic, such premature complexe (PC) can be uncomfortable or even disabling.
Several pharmacological and non-pharmacological measures for their clinical control have
been suggested. However, under certain conditions, the results are limited or the
risk-benefit relationship is arguable.</p><p>Magnesium (Mg) is an alkaline earth metal that participates in several metabolic
processes, such as reactions in ATP generation. It is the second intracellular cation
and the fourth cation of the human body<sup><xref rid="B06" ref-type="bibr">6</xref>-<xref rid="B09" ref-type="bibr">9</xref></sup>. That metal plays a
significant role in maintaining proper cardiac rhythm, because of its action on the
Na/K- ATPase pump<sup><xref rid="B06" ref-type="bibr">6</xref>,<xref rid="B07" ref-type="bibr">7</xref></sup> and its interaction with calcium<sup><xref rid="B10" ref-type="bibr">10</xref></sup>. Approximately half of the body Mg is
within soft tissue cells, while the other half is within bone tissue<sup><xref rid="B08" ref-type="bibr">8</xref>,<xref rid="B11" ref-type="bibr">11</xref></sup>. Less than 1% of Mg is found in the blood, and approximately 0.3%, in
the serum<sup><xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref></sup>. Thus, total body Mg has a weak correlation with its serum
levels, which can be normal in the presence of low intracellular values<sup><xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref></sup>.</p><p>The Mg intake has decreased in the past century<sup><xref rid="B08" ref-type="bibr">8</xref></sup>, probably due to the increased consumption of processed
foods<sup><xref rid="B08" ref-type="bibr">8</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B16" ref-type="bibr">16</xref></sup>, which can be a risk
factor for Mg deficiency. That deficiency can be associated with cardiovascular disease,
such as cardiac arrhythmias<sup><xref rid="B08" ref-type="bibr">8</xref></sup>. In
selected patients, based on a simple treatment strategy, antiarrhythmics drugs, which
can be harmful or poorly tolerated under certain circumstances, can be avoided.
Recently, we have shown that Mg pidolate (MgP), after a 30-day continuous
supplementation, can decrease ectopic beats and improve related symptoms<sup><xref rid="B17" ref-type="bibr">17</xref></sup>. Based on those initial findings, we
assessed the outcome of this cohort of patients in the late follow-up.</p><p>This study was aimed at: 1) assessing the late clinical outcome of patients initially
treated with placebo and/or MgP; 2) assessing whether patients with arrhythmia relapse
in a 15-month follow-up, when treated for the second time, have the same response of the
first treatment; and 3) assessing the response of patients to MgP after initially
receiving placebo.</p></sec><sec sec-type="methods"><title>Methods</title><p>This study's methodology has been previously described when assessing the 30-day
results<sup><xref rid="B17" ref-type="bibr">17</xref></sup>. In the first state of
the treatment, ninety consecutive symptomatic patients were randomized (double-blind) to
receive either 3.0 g/day of MgP, the equivalent of 260 mg of the Mg element, or placebo,
for 30 days. All patients underwent transthoracic echocardiography, and had normal
kidney function (Cockcroft-Gault formula) and structurally normal heart<sup><xref rid="B18" ref-type="bibr">18</xref></sup>.</p><p>The serum levels of Mg, sodium, calcium and potassium were measured before and on the
15<sup>th</sup> and 30<sup>th</sup> day after randomization. The follow-up visits
were monthly conducted to assess symptoms by using a specific questionnaire. As
previously described<sup><xref rid="B17" ref-type="bibr">17</xref></sup>, the
questionnaire was elaborated with the following questions: 1- failures or "leaps", like
a 'somersault' in the chest; 2- cough with palpitations; 3- dizziness; 4- dyspnea; 5-
sweating and/or chest pain. According to the frequency of symptoms, points were
attributed, which resulted in a score, and a two-point drop was considered a criterion
of improvement. In addition, a categorical classification was conducted by asking the
patients whether the symptoms improved, the answers being merely "yes" or "no" (<xref ref-type="fig" rid="f01">Figure 1</xref>). In the long-term follow-up, all patients
underwent 24-hour Holter monitoring twice, independently of symptoms, to assess the PC
frequency. In addition, Holter monitoring (3 channels) was performed whenever symptoms
appeared (before and 30 days of use of MgP).</p><fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><p>This figure shows the score system to assess improvement of symptoms before and
after the drugs in both groups (placebo and magnesium pidolate).</p></caption><graphic xlink:href="abc-103-06-0468-g01"/></fig><p>In the second phase of the study, the patients with symptom relapse, of both the
treatment and placebo groups ("crossing over"), received MgP for 30 more days, according
to the same protocol.</p><sec><title>Statistical analysis</title><p>The densities of PC in both phases of treatment (pre- and post-intervention) were
measured by using mean, standard deviation, median, minimum and maximum
values<sup><xref rid="B19" ref-type="bibr">19</xref></sup>.</p><p>The PC densities were compared between times of treatment and between treatments by
using repeated-measures two-way analysis of variance (ANOVA)<sup><xref rid="B20" ref-type="bibr">20</xref></sup>. A correlation matrix of symmetrical
components was calculated between asssessments<sup><xref rid="B20" ref-type="bibr">20</xref></sup>. Multiple comparisons by using Bonferroni adjustment<sup><xref rid="B21" ref-type="bibr">21</xref></sup> were performed between the treatment
times, and contrast was created to assess whether the improvement in the first
treatment (pre-post 1<sup>st</sup> treatment) differed from that in the second
treatment (pre-post 2<sup>nd</sup> treatment).</p><p>The improvement in symptoms was described at each treatment phase in both groups of
patients, and McNemar tests<sup><xref rid="B19" ref-type="bibr">19</xref></sup> were
performed to assess whether there was difference in the improvement percentages in
each treatment. The results were illustrated by using graphs of mean profiles with
the respective standard errors. The 5% significance level was adopted for all tests.
The SPSS software, version 20.0, was used for statistical analysis.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The 90 patients participating in the first phase of treatment were followed up for 15
months. <xref ref-type="table" rid="t01">Table 1</xref> shows the outcome of the first
intervention. Of the 45 patients initially randomized to receive MgP, 41 (91.1%) were
asymptomatic after the first month assessment, and four relapsed. In subsequent months,
more 13 patients relapsed, adding to a total of 17 relapses (37.8%). All patients were
treated again. The relapse time varied during the 15-month follow-up, and no
statistically significant relapse concentration in a certain time was observed.</p><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><p>Outcome of the first intervention with Magnesium pidolate (MgP) versus placebo
(shown as median)</p></caption><table frame="hsides" rules="rows"><thead><tr><th rowspan="2" colspan="1">Variable</th><th rowspan="2" colspan="1">Group</th><th colspan="2" rowspan="1">1st treatment (N = 90)</th><th rowspan="2" colspan="1">Improvement (%)</th><th rowspan="2" colspan="1">p</th></tr><tr><th rowspan="1" colspan="1">pre</th><th rowspan="1" colspan="1">post 30 days</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>PVC/day</bold>
</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Placebo (N = 45)</td><td align="center" rowspan="1" colspan="1">2634 (194 - 24534)</td><td align="center" rowspan="1" colspan="1">4211 (42 - 22526)</td><td align="center" rowspan="1" colspan="1">1 (-831.7 - 78.4)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">MgP (N = 45)</td><td align="center" rowspan="1" colspan="1">1883 (2 - 38804)</td><td align="center" rowspan="1" colspan="1">165 (0 - 6677)</td><td align="center" rowspan="1" colspan="1">96 (-1250 - 100)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">
<bold>PsVC/day</bold>
</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Placebo (N = 45)</td><td align="center" rowspan="1" colspan="1">176 (0 - 15965)</td><td align="center" rowspan="1" colspan="1">785 (1 - 19861)</td><td align="center" rowspan="1" colspan="1">-5 (-2840 - 75)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">MgP (N = 45)</td><td align="center" rowspan="1" colspan="1">84 (0 - 20019)</td><td align="center" rowspan="1" colspan="1">51 (0 - 15548)</td><td align="center" rowspan="1" colspan="1">62 (-3025 - 100)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">
<bold>PC-Density/hour</bold>
</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Placebo (N = 45)</td><td align="center" rowspan="1" colspan="1">158 (12.1 - 1022.3)</td><td align="center" rowspan="1" colspan="1">199 (24.8 - 938.6)</td><td align="center" rowspan="1" colspan="1">-3 (-794.7 - 19.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">MgP (N = 45)</td><td align="center" rowspan="1" colspan="1">121 (21.1 - 1616)</td><td align="center" rowspan="1" colspan="1">12 (0 - 647.8)</td><td align="center" rowspan="1" colspan="1">87 (-7.7 - 100)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn><p>Mann-Whitney test results, PC: premature complexe; PVC: premature ventricular
complexes; PsVC: premature supraventricular complexes.</p></fn></table-wrap-foot></table-wrap><sec><title>Frequency of premature complexes</title><p>The relapsing patients (17 in the MgP group) who were retreated had a mean reduction
in the PC density of 138.25/hour in both treatments (p &#x0003c; 0.001). No mean
difference was observed in the PC density improvement between the successful initial
treatment and that after relapse (p = 0.159), that is, patients using MgP repeated
the response of the first treatment: significant improvement in symptoms and in PC
(<xref ref-type="table" rid="t02">Table 2</xref> and <xref ref-type="fig" rid="f02">Figure 2</xref>).</p><table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><p>Results of the multiple comparisons of extrasystole density of the groups of
treatment</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th rowspan="1" colspan="1">Comparison</th><th rowspan="1" colspan="1">Mean difference</th><th rowspan="1" colspan="1">Standard error</th><th rowspan="1" colspan="1">t value</th><th rowspan="1" colspan="1">gl</th><th rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td rowspan="5" colspan="1">
<bold>Crossing</bold>
</td><td align="center" rowspan="1" colspan="1">Placebo pre vs post</td><td align="center" rowspan="1" colspan="1">-22.46</td><td align="center" rowspan="1" colspan="1">37.74</td><td align="center" rowspan="1" colspan="1">-0.59</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.999</td></tr><tr><td align="center" rowspan="1" colspan="1">MgP pre vs post</td><td align="center" rowspan="1" colspan="1">224.55</td><td align="center" rowspan="1" colspan="1">37.74</td><td align="center" rowspan="1" colspan="1">5.95</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Placebo vs MgP pre</td><td align="center" rowspan="1" colspan="1">-0.01</td><td align="center" rowspan="1" colspan="1">37.74</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.999</td></tr><tr><td align="center" rowspan="1" colspan="1">Placebo vs MgP post</td><td align="center" rowspan="1" colspan="1">246.99</td><td align="center" rowspan="1" colspan="1">37.74</td><td align="center" rowspan="1" colspan="1">6.54</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">(pre-post) Placebo vs MgP</td><td align="center" rowspan="1" colspan="1">247.00</td><td align="center" rowspan="1" colspan="1">53.38</td><td align="center" rowspan="1" colspan="1">4.63</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td rowspan="2" colspan="1">
<bold>Relapse</bold>
</td><td align="center" rowspan="1" colspan="1">Pre vs Post</td><td align="center" rowspan="1" colspan="1">138.25</td><td align="center" rowspan="1" colspan="1">24.11</td><td align="center" rowspan="1" colspan="1">5.73</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">(pre-post) 1st Treat vs 2nd Treat</td><td align="center" rowspan="1" colspan="1">-66.86</td><td align="center" rowspan="1" colspan="1">46.72</td><td align="center" rowspan="1" colspan="1">-1.43</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">0.159</td></tr></tbody></table><table-wrap-foot><fn><p>vs: versus; result of Bonferroni multiple comparisons.</p></fn></table-wrap-foot></table-wrap><fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mean profiles of extrasystole density in each treatment of relapsing
patients.</p></caption><graphic xlink:href="abc-103-06-0468-g02"/></fig><p>The median value of PVC/day after the first treatment was 3, and was 1872 on Holter
monitoring after relapse. After the new intervention, this frequency decreased to 280
(p &#x0003c; 0.001). Regarding PsVC, the median after the first treatment was 14 PsVC/day,
15 on Holter monitoring after relapse, increasing to 38 after treatment (p &#x0003c;
0.102) (<xref ref-type="table" rid="t03">Table 3</xref>). The density of PC/hour
after the first treatment was 10.3, increasing to 126.1 on relapse, and decreasing to
50.2 after the new treatment (p &#x0003c; 0.001) (<xref ref-type="table" rid="t03">Tables
3</xref> and <xref ref-type="table" rid="t04">4</xref>).</p><table-wrap id="t03" orientation="portrait" position="float"><label>Table 3</label><caption><p>Description of ventricular and supraventricular extrasystoles in each group</p></caption><table frame="hsides" rules="rows"><thead><tr><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="2" colspan="1">Variable</th><th colspan="2" rowspan="1">1st treatment</th><th colspan="2" rowspan="1">Follow-up</th></tr><tr><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">pre</th><th rowspan="1" colspan="1">post 30 days</th><th rowspan="1" colspan="1">pre (follow-up)</th><th rowspan="1" colspan="1">post (follow-up)</th></tr></thead><tbody><tr><td rowspan="3" colspan="1">
<bold>No relapse</bold>
</td><td align="center" rowspan="1" colspan="1">PVC/day</td><td align="center" rowspan="1" colspan="1">2034 (0 - 38804)</td><td align="center" rowspan="1" colspan="1">264 (0 - 6677)</td><td align="center" rowspan="1" colspan="1">7.3 (0 - 710)</td><td align="center" rowspan="1" colspan="1">NA<xref ref-type="table-fn" rid="TFN01">*</xref></td></tr><tr><td rowspan="1" colspan="1">PsVC/day</td><td align="center" rowspan="1" colspan="1">29.5 (0 - 19386)</td><td align="center" rowspan="1" colspan="1">18.5 (0 - 15548)</td><td align="center" rowspan="1" colspan="1">5.5 (0 - 973)</td><td align="center" rowspan="1" colspan="1">NA<xref ref-type="table-fn" rid="TFN01">*</xref></td></tr><tr><td rowspan="1" colspan="1">PC/hour</td><td align="center" rowspan="1" colspan="1">119.9 (34.9 - 1616)</td><td align="center" rowspan="1" colspan="1">15.5 (0 - 647.8)</td><td align="center" rowspan="1" colspan="1">3 (0 - 40.5)</td><td align="center" rowspan="1" colspan="1">NA<xref ref-type="table-fn" rid="TFN01">*</xref></td></tr><tr><td rowspan="3" colspan="1">
<bold>Relapse (N = 17)</bold>
</td><td align="center" rowspan="1" colspan="1">PVC/day</td><td align="center" rowspan="1" colspan="1">1386 (0 - 6497)</td><td align="center" rowspan="1" colspan="1">3 (0 - 1616)</td><td align="center" rowspan="1" colspan="1">1872 (0 - 8040)</td><td align="center" rowspan="1" colspan="1">280 (0 - 3980)</td></tr><tr><td rowspan="1" colspan="1">PsVC/day</td><td align="center" rowspan="1" colspan="1">78 (0 - 20019)</td><td align="center" rowspan="1" colspan="1">14 (0 - 13104)</td><td align="center" rowspan="1" colspan="1">15 (0 - 12020)</td><td align="center" rowspan="1" colspan="1">38 (0 - 7008)</td></tr><tr><td rowspan="1" colspan="1">PC/hour</td><td align="center" rowspan="1" colspan="1">132 (21.1 - 839.7)</td><td align="center" rowspan="1" colspan="1">10.3 (0 - 546)</td><td align="center" rowspan="1" colspan="1">126.1 (33.4 - 511.3)</td><td align="center" rowspan="1" colspan="1">50.2 (1 - 292)</td></tr><tr><td rowspan="3" colspan="1">
<bold>Crossing (N = 21)</bold>
</td><td align="center" rowspan="1" colspan="1">PVC/day</td><td align="center" rowspan="1" colspan="1">3030 (0 - 22502)</td><td align="center" rowspan="1" colspan="1">3002 (0 - 21429)</td><td align="center" rowspan="1" colspan="1">2508 (0 - 22505)</td><td align="center" rowspan="1" colspan="1">689 (0 - 18812)</td></tr><tr><td rowspan="1" colspan="1">PsVC/day</td><td align="center" rowspan="1" colspan="1">2 (0 - 15965)</td><td align="center" rowspan="1" colspan="1">3 (0 - 19861)</td><td align="center" rowspan="1" colspan="1">4 (0 - 15965)</td><td align="center" rowspan="1" colspan="1">1 (0 - 10900)</td></tr><tr><td rowspan="1" colspan="1">PC/hour</td><td align="center" rowspan="1" colspan="1">264.8 (32.5-938.2)</td><td align="center" rowspan="1" colspan="1">299.3(34.6-899.6)</td><td align="center" rowspan="1" colspan="1">264.8 (32.5 - 938.3)</td><td align="center" rowspan="1" colspan="1">48 (0 - 784)</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><label>*</label><p>Not applicable, PC: premature complexe; PVC: premature ventricular
complexes; PsVC: premature supraventricular complexes.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t04" orientation="portrait" position="float"><label>Table 4</label><caption><p>Description of densities of extrasystoles per hour in each group</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1">Group/Treatment</th><th rowspan="1" colspan="1">Time</th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1">SD</th><th rowspan="1" colspan="1">Median</th><th rowspan="1" colspan="1">Minimum</th><th rowspan="1" colspan="1">Maximum</th><th rowspan="1" colspan="1">N</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">
<bold>Placebo</bold>
</td><td align="center" rowspan="1" colspan="1">Pre</td><td align="center" rowspan="1" colspan="1">339.82</td><td align="center" rowspan="1" colspan="1">263.67</td><td align="center" rowspan="1" colspan="1">264.75</td><td align="center" rowspan="1" colspan="1">32.50</td><td align="center" rowspan="1" colspan="1">938.20</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="center" rowspan="1" colspan="1">Post</td><td align="center" rowspan="1" colspan="1">362.28</td><td align="center" rowspan="1" colspan="1">275.71</td><td align="center" rowspan="1" colspan="1">299.25</td><td align="center" rowspan="1" colspan="1">34.58</td><td align="center" rowspan="1" colspan="1">899.60</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td rowspan="2" colspan="1">
<bold>MgP (crossing)</bold>
</td><td align="center" rowspan="1" colspan="1">Pre</td><td align="center" rowspan="1" colspan="1">339.83</td><td align="center" rowspan="1" colspan="1">263.69</td><td align="center" rowspan="1" colspan="1">264.75</td><td align="center" rowspan="1" colspan="1">32.50</td><td align="center" rowspan="1" colspan="1">938.33</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="center" rowspan="1" colspan="1">Post</td><td align="center" rowspan="1" colspan="1">115.29</td><td align="center" rowspan="1" colspan="1">183.47</td><td align="center" rowspan="1" colspan="1">48.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">784.00</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td rowspan="2" colspan="1">
<bold>1st treatment</bold>
</td><td align="center" rowspan="1" colspan="1">Pre</td><td align="center" rowspan="1" colspan="1">238.07</td><td align="center" rowspan="1" colspan="1">245.03</td><td align="center" rowspan="1" colspan="1">132</td><td align="center" rowspan="1" colspan="1">21.08</td><td align="center" rowspan="1" colspan="1">839.67</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="center" rowspan="1" colspan="1">Post</td><td align="center" rowspan="1" colspan="1">66.39</td><td align="center" rowspan="1" colspan="1">137.26</td><td align="center" rowspan="1" colspan="1">10.3</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">546.00</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td rowspan="2" colspan="1">
<bold>Treatment after relapse</bold>
</td><td align="center" rowspan="1" colspan="1">Pre</td><td align="center" rowspan="1" colspan="1">178.28</td><td align="center" rowspan="1" colspan="1">126.75</td><td align="center" rowspan="1" colspan="1">126.08</td><td align="center" rowspan="1" colspan="1">33.42</td><td align="center" rowspan="1" colspan="1">511.25</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="center" rowspan="1" colspan="1">Post</td><td align="center" rowspan="1" colspan="1">73.46</td><td align="center" rowspan="1" colspan="1">78.15</td><td align="center" rowspan="1" colspan="1">50.21</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">292.00</td><td align="center" rowspan="1" colspan="1">17</td></tr></tbody></table><table-wrap-foot><fn><p>SD: standard deviation; MgP: magnesium pidolate</p></fn></table-wrap-foot></table-wrap><p>Only three patients relapsed twice, being retreated, and two of them responded
similarly, with improvement in symptoms and in PC frequency. Only one patient
relapsed three times, and had a good response after the retreatments. The patients
who did not relapse had a low PC frequency on Holter monitoring, with a median of 3
PC/hour (<xref ref-type="table" rid="t03">Table 3</xref>).</p><p>Of the 45 patients treated with placebo in the first phase, 6 (13.3%) improved their
symptoms and 39 (86.7%) remained symptomatic. Of those 39, 21 agreed to receive MgP
and were selected for crossing-over. Patients who did not agree to receive MgP were
excluded from the analysis. The crossing-over patients had a statistically
significant mean reduction in the PC density when using MgP (p &#x0003c; 0.001), while,
when on placebo, no change in density was observed (p &#x0003e; 0.999). The mean
improvement in PC density was 247/hour, greater in the treatment with MgP than in the
first treatment with placebo (p &#x0003c; 0.001) (<xref ref-type="table" rid="t02">Table
2</xref> and <xref ref-type="fig" rid="f03">Figure 3</xref>).</p><fig id="f03" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Mean profiles of density of extrasystoles in each treatment in patients of the
placebo group undergoing crossing-over.</p></caption><graphic xlink:href="abc-103-06-0468-g03"/></fig><p>The median of PVC decreased from 2508/day to 689/day (p &#x0003c; 0.001), and that of
PsVC, from 4/day to 1/day (p &#x0003c; 0.015) (<xref ref-type="table" rid="t03">Table
3</xref>). The density of PC/hour was 264.8 in the pre-treatment phase, dropping
to 48 after the use of MgP (crossing-over) (<xref ref-type="table" rid="t03">Tables
3</xref> and <xref ref-type="table" rid="t04">4</xref>).</p><p>On Holter monitoring, PVC were more frequent, originating mainly (71%) from the
outflow tract of the ventricles.</p></sec><sec><title>Symptoms</title><p>In relapsing patients, the improvement in symptoms of both treatments was
statistically the same (p = 0.125) (<xref ref-type="table" rid="t05">Table 5</xref>).
All 17 relapsing patients improved their symptoms in the first treatment, while 76.5%
improved their symptoms in the relapse treatment. Similar response was obtained in
the score of symptoms and in the categorical response of symptom improvement ('yes'
or 'no').</p><p>The patients using placebo in the initial treatment and MgP in the second one
(crossing-over) had a statistically greater improvement in symptoms with the second
treatment (14.3% <italic>versus</italic> 71.4%, respectively; p &#x0003c; 0.001) (<xref ref-type="table" rid="t05">Table 5</xref>).</p><table-wrap id="t05" orientation="portrait" position="float"><label>Table 5</label><caption><p>Improvement in symptoms of each group of patients for each treatment, and
results of the marginal association test</p></caption><table frame="hsides" rules="rows"><thead><tr><th rowspan="2" colspan="1">Group</th><th rowspan="2" colspan="1">Improvement in symptoms</th><th colspan="2" rowspan="1">1st treatment</th><th colspan="2" rowspan="1">2nd treatment</th><th rowspan="2" colspan="1">p</th></tr><tr><th rowspan="1" colspan="1">n</th><th rowspan="1" colspan="1">%</th><th rowspan="1" colspan="1">n</th><th rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td rowspan="3" colspan="1">
<bold>Crossing</bold>
</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">85.7</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">28.6</td><td rowspan="2" align="center" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">14.3</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">71.4</td></tr><tr><td align="center" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>21</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>100</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>21</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>100</bold>
</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="3" colspan="1">
<bold>Relapse</bold>
</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">23.5</td><td rowspan="2" align="center" colspan="1"> 0.125</td></tr><tr><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">76.5</td></tr><tr><td align="center" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>17</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>100</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>17</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>100</bold>
</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn><p>McNemar test results</p></fn></table-wrap-foot></table-wrap><p>No significant changes in the measurements of serum Mg, potassium and calcium were
observed during the study. No side effects were observed in the long-term
follow-up.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The follow-up results show that the improvement in symptoms by using MgP was maintained
(76.5%) in the relapsing group as compared with the initial treatment. The group using
placebo initially (crossing-over) had a 71.4% improvement in symptoms with MgP
<italic>versus</italic> a 14.3% improvement with placebo.</p><p>The use of MgP was effective in reducing PC. However, because that is mainly a
symptomatic treatment and because the mechanism of PC is multifactorial, symptoms and PC
relapsed in approximately 38% of the cases, indicating that MgP is neither a definitive
nor a curative treatment in late follow-up. However, the patients who could use MgP
again improved their frequency of PC and mainly their symptoms, the latter being this
study's major objective, because the group treated had a structurally normal heart.</p><p>It is worth noting that the patients initially treated with placebo also improved
significantly their symptoms and frequency of PC after using MgP. This confirms that Mg
administration is really better than placebo use.</p><p>The Mg reduces irregular heartbeats, and Mg deficiency should always be considered a
potential factor for cardiac arrhythmias<sup><xref rid="B22" ref-type="bibr">22</xref></sup>. One hypothesis of the pathophysiological mechanisms relates to the
fact that low Mg levels lead to an increase in intracellular calcium and sodium, and to
a decrease in intracellular potassium<sup><xref rid="B07" ref-type="bibr">7</xref>,<xref rid="B08" ref-type="bibr">8</xref></sup>. Those changes in ionic loads cause
membrane potential flotations, destabilizing atrial and ventricular myocardium, causing
arrhythmias.</p><p>The Framingham study<sup><xref rid="B23" ref-type="bibr">23</xref></sup> has shown that
low Mg levels are associated with the development of atrial fibrillation in individuals
with no cardiovascular disease. Patients at intensive care units should undergo
intravenous replacement of Mg for arrhythmias not responding to conventional drugs, such
as <italic>torsades de pointes</italic><sup><xref rid="B15" ref-type="bibr">15</xref></sup>, and arrhythmias caused by digitalis intoxication<sup><xref rid="B24" ref-type="bibr">24</xref></sup>. Similarly to hypomagnesemia, digitalis
inhibits the Na/K ATPase pump, increasing intracellular calcium and the contraction
power of cardiomyocytes, PC being one of the most common arrhythmias in digitalis
intoxication. The Mg deficiency caused by diuretic treatment in heart failure is
associated with a higher incidence of arrhythmias, such as ventricular ectopy<sup><xref rid="B06" ref-type="bibr">6</xref>,<xref rid="B08" ref-type="bibr">8</xref>,<xref rid="B25" ref-type="bibr">25</xref></sup>. High concentrations of catecholamines
can lead to the exit of intracellular Mg to the extracellular compartment, resulting in
Mg reduction in the tissues, causing arrhythmias, especially in cardiac surgeries and in
congestive heart failure patients<sup><xref rid="B06" ref-type="bibr">6</xref></sup>.</p><p>According to Kleivay and Milne<sup><xref rid="B26" ref-type="bibr">26</xref></sup>, the
recommended daily Mg intake is 320 mg/day. Higher daily doses might be required by
patients on diuretics, more prone to Mg level reduction, and, thus, with a higher
potential and more susceptible to the development of ES<sup><xref rid="B26" ref-type="bibr">26</xref></sup>. Martynov and Akatova<sup><xref rid="B27" ref-type="bibr">27</xref></sup> have followed up, for 15 years, 31 patients with mitral
valve prolapse, who, during that time, regularly used Mg preparations for three months,
twice a year. A reduction in the following parameters were observed: mean and maximum
heart rate; number of tachycardia episodes; QT interval duration; and incidence of
paroxysmal supraventricular tachycardia and PC. In addition, improvements in quality of
life and in &#x0200b;&#x0200b;sympathetic tone were observed.</p><p>More recently, Del Gobbo et al<sup><xref rid="B28" ref-type="bibr">28</xref></sup> have
assessed obese adults with type 2 diabetes, and have shown that low serum Mg levels were
associated with a high prevalence of PVC.</p><p>Our previous study, assessing 60 individuals with PVC and PsVC, has shown an improvement
in the frequency of arrhythmia and mainly in symptoms<sup><xref rid="B17" ref-type="bibr">17</xref></sup>. Our current results indicate a significant improvement
in PVC of the outflow tract. Right ventricular outflow tract is the most common origin
of PVC in patients without structural heart disease<sup><xref rid="B29" ref-type="bibr">29</xref></sup>. That site might have remnant cells of the neural crest and of
adrenergic modulation. The Mg reduction in those cells might be related to sympathetic
modulation, more evident in the ventricles.</p><p>All those studies have shown that Mg intake can be a practical alternative to treat some
arrhythmias. Considering its low cost, its efficacy and safety, the increase in daily Mg
intake should be considered for symptomatic patients with PC and a structurally normal
heart.</p><sec><title>Limitations</title><p>Intracellular Mg was not measured, but the measurement of serum Mg levels has shown
that supplementation to be safe and effective. The specific score for symptoms has
not been validated, because it does not exist in the literature. However, a
categorical assessment ('yes' or 'no') has also been performed, showing a good
correlation between the reduction in PC frequency and improvement in symptoms. In
addition, this study was not aimed at preventing life-threatening arrhythmias. These
data should not be used to justify the treatment of patients for that purpose,
especially those with heart diseases.</p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Some patients on MgP had relapse of symptoms and PC, indicating that MgP is neither a
definitive nor a curative treatment in late follow-up. However, improvement in the PC
frequency and symptoms was observed in the second phase of treatment, after relapse,
being similar to the response in the first phase of treatment. Treatment with MgP, even
after the first phase with placebo, improved the symptoms and PC density of the
population studied (structurally normal heart).</p><p>The increase in daily Mg intake should be considered for patients with PC and
structurally normal heart.</p></sec></body><back><fn-group><fn fn-type="con"><p>
<bold>Author contributions</bold>
</p><p>Conception and design of the research: De Falco CNML, Darrieux FCC, Scanavacca M;
Acquisition of data: De Falco CNML, Darrieux FCC, Sacilotto L; Analysis and
interpretation of the data: De Falco CNML, Darrieux FCC, Sacilotto L, Pisani C;
Statistical analysis: De Falco CNML, Darrieux FCC, Pisani C; Obtaining financing: De
Falco CNML; Writing of the manuscript: De Falco CNML, Darrieux FCC, Scanavacca M;
Critical revision of the manuscript for intellectual content: De Falco CNML, Darrieux
FCC, Sacilotto L, Lara S, Ramires JAF, Sosa E, Wu TC, Hachul D, Scanavacca M.</p></fn><fn fn-type="conflict"><p>
<bold>Potential Conflict of Interest</bold>
</p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="financial-disclosure"><p>
<bold>Sources of Funding</bold>
</p><p>There were no external funding sources for this study.</p></fn><fn fn-type="other"><p>
<bold>Study Association</bold>
</p><p>This article results from the continuation of the doctoral dissertation by Cristina
N&#x000e1;dja M. Lima De Falco, from Faculdade de Medicina da Universidade de S&#x000e3;o Paulo.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Prof. Dr. Dalmo Moreira and Prof. Dr. Ricardo Alkmim Teixeira for their
precious suggestions in the first phase of this project, Prof. Dr. Ant&#x000f4;nio Carlos
Pereira Barretto and Prof. Dr. Alfredo J. Mansur for all the encouragement, and Rog&#x000e9;rio
Ruscitto Prado for his support in the statistical analysis.</p></ack><ref-list><title>References</title><ref id="B01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barret</surname><given-names>PA</given-names></name><name><surname>Peter</surname><given-names>CT</given-names></name><name><surname>Swan</surname><given-names>HJ</given-names></name><name><surname>Singh</surname><given-names>BN</given-names></name><name><surname>Mandel</surname><given-names>WJ</given-names></name></person-group><article-title>The frequency and prognostic significance of electrocardiographic
abnormalities in clinically normal individuals</article-title><source>Prog Cardiovasc Dis</source><year>1981</year><volume>23</volume><issue>4</issue><fpage>299</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">6162171</pub-id></element-citation></ref><ref id="B02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Paula</surname><given-names>RS</given-names></name><name><surname>Antelmi</surname><given-names>I</given-names></name><name><surname>Vincenzi</surname><given-names>MA</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>CD</given-names></name><name><surname>Artes</surname><given-names>R</given-names></name><name><surname>Grupi</surname><given-names>CJ</given-names></name><etal>et al</etal></person-group><article-title>Cardiac arrhythmias and atrioventricular block in a cohort of
asymptomatic individuals without heart disease</article-title><source>Cardiology</source><year>2007</year><volume>108</volume><issue>2</issue><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">17008799</pub-id></element-citation></ref><ref id="B03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>V</given-names></name><name><surname>Jensen</surname><given-names>G</given-names></name><name><surname>Schnohr</surname><given-names>P</given-names></name><name><surname>Hansen</surname><given-names>JF</given-names></name></person-group><article-title>Premature ventricular beats in healthy adult subjects 20 to 79 years
of age</article-title><source>Eur Heart J</source><year>1985</year><volume>6</volume><issue>4</issue><fpage>335</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">2411563</pub-id></element-citation></ref><ref id="B04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wajngarten</surname><given-names>M</given-names></name><name><surname>Grupi</surname><given-names>C</given-names></name><name><surname>Bellotti</surname><given-names>GM</given-names></name><name><surname>Da Luz</surname><given-names>PL</given-names></name><name><surname>Azul</surname><given-names>LG</given-names></name><name><surname>Pileggi</surname><given-names>F</given-names></name></person-group><article-title>Frequency and significance of cardiac rhythm disturbances in healthy
elderly individuals</article-title><source>J Electrocardiol</source><year>1990</year><volume>23</volume><issue>2</issue><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">2341817</pub-id></element-citation></ref><ref id="B05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiss</surname><given-names>RG</given-names></name><name><surname>Averill</surname><given-names>KH</given-names></name><name><surname>Lamb</surname><given-names>LE</given-names></name></person-group><article-title>Electrocardiographic findings in 67,375 asymptomatic subjects. III.
Ventricular rhythms</article-title><source>Am J Cardiol</source><year>1960</year><volume>6</volume><fpage>96</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">13855920</pub-id></element-citation></ref><ref id="B06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swaminathan</surname><given-names>R</given-names></name></person-group><article-title>Magnesium metabolism and disorders</article-title><source>Clin Biochem Rev</source><year>2003</year><volume>24</volume><issue>2</issue><fpage>47</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">18568054</pub-id></element-citation></ref><ref id="B07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Carter</surname><given-names>A</given-names></name></person-group><article-title>Magnesium: the forgotten electrolyte</article-title><source>Aust Prescr</source><year>2007</year><volume>30</volume><fpage>102</fpage><lpage>105</lpage></element-citation></ref><ref id="B08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gums</surname><given-names>JG</given-names></name></person-group><article-title>Magnesium in cardiovascular and other disorders</article-title><source>Am J Health Syst Pharm</source><year>2004</year><volume>61</volume><issue>15</issue><fpage>1569</fpage><lpage>1576</lpage><pub-id pub-id-type="pmid">15372830</pub-id></element-citation></ref><ref id="B09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gums</surname><given-names>JG</given-names></name><name><surname>Stier-Carson</surname><given-names>D</given-names></name><name><surname>Hedrix</surname><given-names>GH</given-names></name><name><surname>Weart</surname><given-names>GH</given-names></name><name><surname>De Oca</surname><given-names>GM</given-names></name></person-group><article-title>Effect of magnesium and potassium on cardiac function: the role of
spironolactone</article-title><source>J Pharm Technol</source><year>1990</year><volume>6</volume><fpage>10</fpage><lpage>14</lpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huskisson</surname><given-names>E</given-names></name><name><surname>Maggini</surname><given-names>S</given-names></name><name><surname>Ruf</surname><given-names>M</given-names></name></person-group><article-title>The role of vitamins and minerals in energy metabolism and
well-being</article-title><source>J Int Med Res</source><year>2007</year><volume>35</volume><issue>3</issue><fpage>277</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">17593855</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elin</surname><given-names>RJ</given-names></name></person-group><article-title>Magnesium: the fifth but forgotten electrolyte</article-title><source>Am J Clin Pathol</source><year>1994</year><volume>102</volume><issue>5</issue><fpage>616</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">7942627</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elin</surname><given-names>RJ</given-names></name></person-group><article-title>Laboratory tests for the assessment of magnesium status in
humans</article-title><source>Magnes Trace Elem</source><year>1991</year><volume>92</volume><issue>2-4</issue><fpage>172</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">1844550</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnaud</surname><given-names>MJ</given-names></name></person-group><article-title>Update on the assessment of magnesium status</article-title><source>Br J Nutr</source><year>2008</year><volume>99</volume><issue>Suppl 3</issue><fpage>S24</fpage><lpage>S36</lpage><pub-id pub-id-type="pmid">18598586</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arsenian</surname><given-names>MA</given-names></name></person-group><article-title>Magnesium and cardiovascular disease</article-title><source>Prog Cardiovasc Dis</source><year>1993</year><volume>35</volume><issue>4</issue><fpage>271</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">7678179</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purvis</surname><given-names>JR</given-names></name><name><surname>Movahed</surname><given-names>A</given-names></name></person-group><article-title>Magnesium disorders and cardiovascular diseases</article-title><source>Clin Cardiol</source><year>1992</year><volume>15</volume><issue>8</issue><fpage>556</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">1499184</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawano</surname><given-names>Y</given-names></name><name><surname>Matsuoka</surname><given-names>H</given-names></name><name><surname>Takishita</surname><given-names>S</given-names></name><name><surname>Omae</surname><given-names>T</given-names></name></person-group><article-title>Effects of magnesium supplementation in hypertensive patients:
assessment by office, home, and ambulatory blood pressures</article-title><source>Hypertension</source><year>1998</year><volume>32</volume><issue>2</issue><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">9719052</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falco</surname><given-names>CN</given-names></name><name><surname>Grupi</surname><given-names>C</given-names></name><name><surname>Sosa</surname><given-names>E</given-names></name><name><surname>Scanavacca</surname><given-names>M</given-names></name><name><surname>Hachul</surname><given-names>D</given-names></name><name><surname>Lara</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Successful improvement of frequency and symptoms of premature
complexes after oral magnesium administration</article-title><source>Arq Bras Cardiol</source><year>2012</year><volume>98</volume><issue>6</issue><fpage>480</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">22584491</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helou</surname><given-names>R</given-names></name></person-group><article-title>Should we continue to use the Cockcroft-Gault formula?</article-title><source>Nephron Clin Pract</source><year>2010</year><volume>116</volume><issue>3</issue><fpage>c172</fpage><lpage>c185</lpage><pub-id pub-id-type="pmid">20606477</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kirkwood</surname><given-names>BR</given-names></name><name><surname>Sterne</surname><given-names>JAC</given-names></name></person-group><source>Essential medical statistics</source><edition>2nd ed</edition><publisher-loc>Massachusetts, USA</publisher-loc><publisher-name>Blackwell Science</publisher-name><year>2006</year></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>JM</given-names></name><name><surname>Andrade</surname><given-names>DF</given-names></name></person-group><year>2000</year><chapter-title>Analysis of longitudinal data</chapter-title><person-group person-group-type="author"><collab>Handbook of statistics</collab></person-group><person-group person-group-type="editor"><name><surname>Sen</surname><given-names>P.K.</given-names></name><name><surname>Rao</surname><given-names>C.R.</given-names></name></person-group><volume>18</volume><source>bio-environmental and public health statistics</source><publisher-loc>Amsterdam</publisher-loc><publisher-name>North Holland</publisher-name><fpage>115</fpage><lpage>160</lpage></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kuntner</surname><given-names>M</given-names></name><name><surname>Nachtsheim</surname><given-names>C</given-names></name><name><surname>Neter</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><source>Applied linear statistical models</source><edition>4th ed</edition><publisher-loc>Illinois, USA</publisher-loc><publisher-name>McGraw Hill / Irwin</publisher-name><year>1996</year></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>GM</given-names></name><name><surname>Rude</surname><given-names>RK</given-names></name></person-group><article-title>Magnesium deficiency in critical illness</article-title><source>J Intensive Care Med</source><year>2005</year><volume>20</volume><issue>1</issue><fpage>3</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">15665255</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>AM</given-names></name><name><surname>Lubitz</surname><given-names>SA</given-names></name><name><surname>Sullivan</surname><given-names>LM</given-names></name><name><surname>Sun</surname><given-names>JX</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name><etal>et al</etal></person-group><article-title>Low serum magnesium and the development of atrial fibrillation in the
community: the Framingham Heart Study</article-title><source>Circulation</source><year>2013</year><volume>127</volume><issue>1</issue><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">23172839</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iseri</surname><given-names>LT</given-names></name><name><surname>Allen</surname><given-names>BJ</given-names></name><name><surname>Brodsky</surname><given-names>MA</given-names></name></person-group><article-title xml:lang="pt">Terapia de magnesio en arritmias cardiacas en medicina
de cuidados cr&#x000ed;ticos</article-title><source>Revista de Cuidados Intensivos em Medicina</source><year>2005</year><volume>20</volume><issue>1</issue><fpage>3</fpage><lpage>17</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceremuzynski</surname><given-names>L</given-names></name><name><surname>Gebalska</surname><given-names>J</given-names></name><name><surname>Wolk</surname><given-names>R</given-names></name><name><surname>Makowska</surname><given-names>E</given-names></name></person-group><article-title>Hypomagnesemia in heart failure with ventricular arrhythmias.
Beneficial effects of magnesium supplementation</article-title><source>J Intern Med</source><year>2000</year><volume>24</volume><issue>1</issue><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">10672134</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klevay</surname><given-names>LM</given-names></name><name><surname>Milne</surname><given-names>DB</given-names></name></person-group><article-title>Low dietary magnesium increases supraventricular
ectopy</article-title><source>Am J Clin Nutr</source><year>2002</year><volume>75</volume><issue>3</issue><fpage>550</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">11864862</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martynov</surname><given-names>Al</given-names></name><name><surname>Akatova</surname><given-names>EV</given-names></name></person-group><article-title>Fifteen years experience of the use of magnesium preparations in
patients with mitral valve prolapse</article-title><source>Kardiologiia</source><year>2011</year><volume>51</volume><issue>6</issue><fpage>60</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">21878073</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Gobbo</surname><given-names>LC</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Poirier</surname><given-names>P</given-names></name><name><surname>Dewailly</surname><given-names>E</given-names></name><name><surname>Elin</surname><given-names>RJ</given-names></name><name><surname>Egeland</surname><given-names>GM</given-names></name></person-group><article-title>Low serum magnesium concentrations are associated with a high
prevalence of premature ventricular complexes in obese adults with type 2
diabetes</article-title><source>Cardiovasc Diabetol</source><year>2012</year><volume>11</volume><issue>1</issue><fpage>23</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">22405520</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darrieux</surname><given-names>FC</given-names></name><name><surname>Scanavacca</surname><given-names>MI</given-names></name><name><surname>Hachul</surname><given-names>DT</given-names></name><name><surname>Melo</surname><given-names>SL</given-names></name><name><surname>D'&#x000c1;villa</surname><given-names>AB</given-names></name><name><surname>Grupi</surname><given-names>CJ</given-names></name><etal>et al</etal></person-group><article-title>Radiofrequency catheter ablation of premature ventricular contractions
originating in the right ventricular outflow tract</article-title><source>Arq Bras Cardiol</source><year>2007</year><volume>88</volume><issue>3</issue><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">17533466</pub-id></element-citation></ref></ref-list></back></article>